

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 286)**

### **SUPPLEMENTAL AND CLARIFICATION ANNOUNCEMENT IN RELATION TO PROPOSED ADOPTION OF SHARE AWARD SCHEME**

Reference is made to the announcement (the “**Announcement**”) of Common Splendor International Health Industry Group Limited (the “**Company**”) dated 5 July 2018 in relation to the proposed adoption of the Scheme. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Company would like to supplement and clarify to the Shareholders and potential investors of the Company the following information relating to the terms of the Scheme:

#### **Operation of the Scheme**

##### *Vesting and lapse*

The Company wishes to supplement that the relevant Awarded Shares made to the Selected Participant who is found not to be an Eligible Person anymore or is deemed to cease to be an Eligible Person, if lapsed, shall remain part of the Trust Fund unless the Board determines otherwise at their absolute discretion. Such Selected Participant shall have no right or claim against the Company, any other member of the Group, the Board, the Trust or the Trustee or with respect to those or any other Shares or any right thereto or interest therein in any way.

##### *Voting Rights*

The Company wishes to clarify that the paragraph under this heading shall be read as follows:

The Trustee shall not exercise the voting rights in respect of any Shares held by it under the Trust (if any) (including but not limited to the Awarded Shares, any bonus Shares and scrip Shares derived therefrom).

## **Scheme limit**

The Company wishes to clarify that the section under this heading shall be amended as follows:

No shares shall be subscribed for and/or purchased pursuant to the Scheme nor any amounts paid to the Trustee for the purpose of making such a subscription and/or purchase, if as a result of such subscription and/or purchase, the number of Shares administered under the Scheme would represent 10% or more of the number of the issued Shares from time to time without Shareholders' approval.

Under the rules of the Scheme, there is no specified limit on the maximum number of Awarded Shares which may be granted to a single Selected Participant under the Scheme.

## **SCHEME MANDATE**

The Company would like to clarify that the an ordinary resolution will be proposed at the SGM to grant the Scheme Mandate to the Directors to allot and issue up to not more than 3% of the total number of issued Shares as at the date of passing such resolution pursuant to Rule 13.36(1) of the Listing Rules prior to allotting and issuing of new Shares to the Trustee, details of which will be set out in the circular to be dispatched by the Company.

## **DEFINITIONS**

The Company would like to clarify that the definition of Scheme Mandate shall be amended as follows:

“Scheme Mandate”                      the specific mandate to be granted by the Shareholders at the SGM to the Directors;

Save as disclosed above, all other information in the Announcement remains unchanged.

By Order of the Board of  
**Common Splendor International  
Health Industry Group Limited**  
**Cheung Wai Kuen**  
*Chairman*

Hong Kong, 8 August 2018

*As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Lin Jiang and Mr. Hou Kai Wen as non-executive Directors; and Mr. Mai Yang Guang, Mr. Lam Chi Wing and Mr. Wong Yiu Kit, Ernest as independent non-executive Directors.*